Related Party Transactions (Tables)

6 Months Ended

12 Months Ended

Jun. 30, 2025

Dec. 31, 2024

Related Party Transactions [Abstract]

Schedule of Remuneration Attributed to Key Management Personnel

Remuneration attributed to key management personnel are summarized as follows:

	Three months ended June 30, 2025		Three months ended June 30, 2024			Six months ended June 30, 2025		Six months ended June 30, 2024
Consulting fees	$	147,700		80,000			595,400		160,833
Director fees		83,290		-			83,290		-
Salaries		-		170,641			26,228		377,656
Share-based compensation		15,842		(54,859	)		36,616		(32,583	)
	$	246,832		195,782			741,534		505,906

Remuneration attributed to key management personnel are summarized as follows:

	December 31, 2024		December 31, 2023
Consulting fees	$	757,233	$	230,000
Salaries		539,174		633,957
Director fees		165,000		-
Share-based compensation		23,861		357,349
	$	1,485,268	$	1,221,306

Schedule of Fair Value, as Calculated on the Grant Date, to Each Related Party

Details of the fair value, as calculated on the grant date, to each related party in the current and prior periods, and the related expense recorded for the six months ended June 30, 2025 and 2024 is as follow:

	Six Months Ended June 30, 2025		Six Months Ended June 30, 2024			Grant date fair value
Braeden Lichti, Non-executive Chairman	$	11	$	(5,355	)	$	50,995
Graydon Bensler, CEO, CFO and Director		11		1,502			50,995
Jordan Plews, Former Director and former CEO of Skincare and BioSciences2		11		1,502			50,995
Tim Sayed, Former Chief Medical Officer and Former Director1		-		1,502			50,995
Jeffrey Parry, Director		6,428		13,349			107,669
Crystal Muilenburg, Former Director1		-		(41,668	)		210,245
Julie Daley, Director		19,592		53,643			210,245
George Kovalyov, Director		10,563		10,308			52,845
Brenda Buechler, Former Chief Marketing Officer1		-		(36,918	)		143,671
Christoph Kraneiss, Former Chief Commercial Officer1		-		(30,448	)		121,243
	$	36,616	$	(32,583	)	$	1,049,898

¹ 379 options of related parties were forfeited and or cancelled during the year ended December 31, 2024

² 143 options of Jordan Plews were cancelled during the three months ended June 30, 2025

Details of the fair value of the options granted to each individual and the related expense recorded for the years ended December 31, 2024 and 2023 are as follow:

	December 31, 2024			December 31, 2023		Fair value of stock options granted
Braeden Lichti, Non-executive Chairman	$	2,069		$	6,563	$	50,995
Graydon Bensler, CEO, CFO and Director		2,069			6,563		50,995
Jordan Plews, Former Director and former CEO of Skincare and BioSciences		2,069			6,563		50,995
Tim Sayed, Former Chief Medical Officer and Former Director1		(4,291	)		6,563		50,995
Jeffrey Parry, Director		22,923			29,855		107,669
Julie Daley, Director		82,070			98,613		210,245
Crystal Muilenburg, Former Director1		(41,668	)		82,252		210,245
George Kovalyov, Director		25,987			-		121,243
Brenda Buechler, Former Chief Marketing Officer1		(36,918	)		62,705		143,671
Christoph Kraneiss, Former Chief Commercial Officer1		(30,449	)		57,672		121,243
	$	23,861		$	357,349	$	1,118,296

¹ 379 options of related parties were forfeited in during the year ended December 31, 2024.